![Edgar Charles](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Edgar Charles
Technik-/Wissenschafts-/F&E-Leiter bei
CLIMB BIO, INC.
Profil
Edgar D.
Charles is Chief Medical Officer at Climb Bio, Inc. since 2025.
Dr. Charles was Vice President at Bristol Myers Squibb Co. from 2015 to 2025.
Dr. Charles completed undergraduate studies at The University of Chicago, graduate studies at The Rockefeller University, and earned a doctorate from The University of Alabama School of Medicine.
Aktive Positionen von Edgar Charles
| Unternehmen | Position | Beginn |
|---|---|---|
| CLIMB BIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 18.06.2025 |
Ehemalige bekannte Positionen von Edgar Charles
| Unternehmen | Position | Ende |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2025 |
Ausbildung von Edgar Charles
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
80
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Rockefeller University
 The Rockefeller University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Alabama School of Medicine
 The University of Alabama School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eliem Therapeutics, Inc.
 Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
